touchONCOLOGY joins Dr Alexander Spira (Virginia Cancer Specialists, Fairfax, VA, USA) at WCLC 2021 to discuss the current, ongoing PERLA phase II clinical trial, that explores the efficacy of dostarlimab + chemotherapy versus pembrolizumab + chemotherapy in metastatic non-squamous non-small cell lung cancer.
ClinicalTrials.gov Identifier: NCT04581824
Questions
1. What are the potential advantages of dostarlimab in the treatment of patients with NSCLC? (00:11-01:05)
2. What are the aims and design of the PERLA study? (01:05-01:39)
3. What are the inclusion and exclusion criteria of the study? (01:39-02:05)
4. When are data expected? (02:05-02:32)
Disclosures: Alexander Spira discloses Leadership involvement with NEXT Oncology Virginia; Stock and Other Ownership Interests from Eli Lilly; Honoraria from CytomX Therapeutics, AstraZeneca/MedImmune, Merck, Takeda, Amgen, Janssen Oncology, Novartis, Bristol-Myers Squibb and Bayer; Consulting or Advisory Roles from Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone Oncology, Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Array BioPharma, AstraZeneca/MedImmune, AstraZeneca/MedImmune, Merck, Bristol-Myers Squibb; Research Funding for his Institution from LAM Therapeutics, Roche, AstraZeneca; Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Newlink Genetics, Incyte, Abbvie, Ignyta, LAM Therapeutics, Trovagene, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals, Bristol-Myers Squibb, Loxo, Arch Therapeutics, Gritstone, Plexxikon, Amgen, Loxo, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, ADCT and Rubius.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 WCLC Annual Meeting.
